JunD protects against chronic kidney disease by regulating paracrine mitogens.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
      Paracrine Communication*; Kidney Diseases/*metabolism ; Mitogens/*metabolism ; Proto-Oncogene Proteins c-jun/*metabolism; Animals ; Cell Division ; Chronic Disease ; Epidermal Growth Factor/metabolism ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Humans ; Kidney/metabolism ; Kidney/pathology ; Kidney Diseases/pathology ; Mice ; Mice, Knockout ; Proto-Oncogene Proteins c-jun/genetics ; Signal Transduction/physiology ; Transcription Factor AP-1/metabolism ; Transforming Growth Factor alpha/metabolism ; Up-Regulation
    • Abstract:
      The AP-1 transcription factor, composed of Jun and Fos proteins, plays a crucial role in the fine tuning of cell proliferation. We showed previously that AP-1 complexes are activated during the proliferative response that parallels the development of renal lesions after nephron reduction, but little is known about the specific role of individual Jun/Fos components in the deterioration process. Here we used JunD knockout (JunD-/-) mice and an experimental model of chronic renal injury (75% nephron reduction) to explore the role of JunD. Nephron reduction resulted in an initial compensatory growth phase that did not require JunD. JunD, however, was essential to inhibit a second wave of cell proliferation and to halt the development of severe glomerular sclerosis, tubular dilation, and interstitial fibrosis. We show that the effects of junD inactivation are not cell autonomous and involve upregulation of the paracrine mitogen, TGF-alpha. Expression of a transgene (REM) encoding a dominant negative isoform of the EGFR, the receptor for TGF-alpha, prevented the second wave of cell proliferation and the development of renal lesions in bitransgenic JunD-/-/REM mice. We propose that JunD is part of a regulatory network that controls proliferation to prevent pathological progression in chronic renal diseases.
    • References:
      Hypertension. 2000 Aug;36(2):282-90. (PMID: 10948091)
      Curr Opin Nephrol Hypertens. 1999 Jul;8(4):465-72. (PMID: 10491742)
      J Am Soc Nephrol. 2000 Jan;11(1):39-46. (PMID: 10616838)
      Development. 2000 Jan;127(1):143-53. (PMID: 10654608)
      Exp Nephrol. 2000 Mar-Apr;8(2):104-14. (PMID: 10729750)
      J Biol Chem. 2000 Jun 16;275(24):18297-301. (PMID: 10748057)
      J Clin Invest. 2000 Jul;106(2):225-34. (PMID: 10903338)
      Physiol Genomics. 1999 Aug 31;1(2):101-5. (PMID: 11015567)
      Oncogene. 2001 Apr 30;20(19):2401-12. (PMID: 11402336)
      Am J Pathol. 2001 Aug;159(2):547-60. (PMID: 11485913)
      Mol Cell. 2000 Nov;6(5):1109-19. (PMID: 11106750)
      Am J Pathol. 2002 Feb;160(2):721-30. (PMID: 11839593)
      Kidney Int. 1984 Aug;26(2):137-43. (PMID: 6239058)
      J Histochem Cytochem. 1987 Jan;35(1):55-65. (PMID: 3794309)
      J Cell Biol. 1977 Nov;75(2 Pt 1):573-85. (PMID: 264124)
      EMBO J. 1989 May;8(5):1433-9. (PMID: 2504580)
      Kidney Int. 1990 Jun;37(6):1515-21. (PMID: 2362405)
      Am J Physiol. 1990 Oct;259(4 Pt 2):F553-8. (PMID: 2221092)
      Histochemistry. 1991;95(4):351-6. (PMID: 1708751)
      J Am Soc Nephrol. 1991 Feb;1(8):1048-53. (PMID: 1912403)
      Biochim Biophys Acta. 1991 Dec 10;1072(2-3):129-57. (PMID: 1751545)
      J Exp Med. 1992 May 1;175(5):1413-6. (PMID: 1569407)
      Kidney Int. 1992 Aug;42(2):354-63. (PMID: 1405318)
      J Cell Biol. 1993 Jul;122(1):199-208. (PMID: 8100231)
      Cell. 1994 Feb 25;76(4):747-60. (PMID: 8124713)
      Oncogene. 1994 Jul;9(7):2105-7. (PMID: 8208558)
      Kidney Int. 1994 May;45(5):1510-21. (PMID: 8072266)
      J Lab Clin Med. 1994 Sep;124(3):386-94. (PMID: 8083581)
      Am J Physiol. 1995 May;268(5 Pt 2):F793-801. (PMID: 7539585)
      Annu Rev Physiol. 1995;57:263-78. (PMID: 7778868)
      Pharmacol Rev. 1995 Mar;47(1):51-85. (PMID: 7784480)
      Kidney Int. 1995 May;47(5):1285-94. (PMID: 7637258)
      Kidney Int. 1995 Nov;48(5):1451-8. (PMID: 8544401)
      Kidney Int. 1996 Mar;49(3):666-78. (PMID: 8648907)
      Anal Biochem. 1995 Dec 10;232(2):225-30. (PMID: 8747479)
      Oncogene. 1997 Feb 20;14(7):819-30. (PMID: 9047389)
      J Am Soc Nephrol. 1997 Mar;8(3):368-75. (PMID: 9071705)
      Exp Nephrol. 1997 Mar-Apr;5(2):126-31. (PMID: 9108994)
      Kidney Int Suppl. 1997 Sep;60:S70-6. (PMID: 9285906)
      J Clin Invest. 1998 Mar 1;101(5):935-9. (PMID: 9486961)
      Biochim Biophys Acta. 1997 Dec 31;1362(2-3):252-62. (PMID: 9540856)
      Kidney Int Suppl. 1998 Apr;65:S68-73. (PMID: 9551435)
      Am J Pathol. 1999 Mar;154(3):891-7. (PMID: 10079267)
      Kidney Int. 1999 Jul;56(1):333-7. (PMID: 10411710)
      Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10830-5. (PMID: 10485911)
      Kidney Int. 2000 Oct;58(4):1420-30. (PMID: 11012877)
    • Accession Number:
      0 (Mitogens)
      0 (Proto-Oncogene Proteins c-jun)
      0 (Transcription Factor AP-1)
      0 (Transforming Growth Factor alpha)
      62229-50-9 (Epidermal Growth Factor)
      EC 2.7.10.1 (ErbB Receptors)
    • Publication Date:
      Date Created: 20030917 Date Completed: 20031103 Latest Revision: 20181130
    • Publication Date:
      20221213
    • Accession Number:
      PMC193664
    • Accession Number:
      10.1172/JCI17647
    • Accession Number:
      12975469